News

Another treatment has joined the long list of compounds that have failed to show effectiveness against Alzheimer’s disease. Three Phase 3 clinical trials showed that idalopirdine was unable to improve more than 2,500 patients’ cognition. A Phase 2 trial suggesting that the treatment was effective has led to researchers speculating…

ProMIS Neurosciences’ Alzheimer’s therapy PMN310 attacks toxic forms of a protein linked to the disease but not normal forms, a preclinical-trial study indicates. Other therapies go after both forms of amyloid beta, giving PMN310 an important safety edge, ProMIS said. The study involved both human brain cells in a lab…

Takeda Pharmaceutical Company and Denali Therapeutics are teaming up to develop three treatments for Alzheimer’s disease and other neurodegenerative diseases. They will use Denali’s Antibody Transport Vehicle technology to get the therapies past the blood-brain barrier so they are able to work where they are needed — in the…

Servier and Treventis will work together on therapies that can circumvent the misfolded proteins involved in Alzheimer’s and other neurodegenerative diseases. The goal is to develop compounds that prevent the brain’s accumulation of two faulty proteins associated with the disorders — amyloid beta and tau. Servier is an international pharmaceutical concern led…

An approved treatment for diabetes may help people with Alzheimer’s, a study reports. The research, “Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease,” was published in the journal Brain Research. Many scientists have tried without success to develop Alzheimer’s…

The pharmaceutical company Cortexyme announced that the first group of participants has been dosed in the Phase 1 clinical trial of its lead compound, COR388, for the treatment of Alzheimer’s disease. Because no new successful developments have emerged in Alzheimer’s therapeutics in the last 15 years, researchers have been trying…

Eisai and Biogen had hoped that using an advanced statistical method to analyze Phase 2 clinical trial results would show at 12 months rather than the normal 18 that their Alzheimer’s therapy BAN2401 was effective. But an independent trial review body declared the 12-month results inconclusive, so the Japanese and…

With 2017 behind us, Alzheimer’s News Today looks forward to bringing our readers news and updates on Alzheimer’s disease research discoveries, treatment developments, clinical trials, and events in the year ahead. But as a reminder of all the great work being done to find treatments and improve the lives…

Pain Therapeutics’ Alzheimer’s therapy PTI-125 was safe, and patients tolerated it well, a Phase 1 clinical trial shows. The therapy is aimed at countering a faulty version of the filamin A protein. Scientists believe this abnormal version contributes to Alzheimer’s by facilitating the buildup of toxic nerve cell plaque and promoting…

BAN2401, an investigational anti-amyloid beta antibody therapy for Alzheimer’s disease, has failed to reach the primary endpoint of a Phase 2 clinical trial measured after 12 months of therapy. Study 201 will continue following the predefined protocol, where a comprehensive analysis will be performed after an 18-month treatment period. Final results…